According to patient recorded outcomes, the IN-Motion151 study met its co-primary endpoint of progression-free survival (PFS). Lead author Bernard Escudier, MD, of the Institut Gustave Roussy in Villejuif, France, while presenting at the 2018 annual meeting of the American Society of Clinical Oncology, said that “Patients treated with atezolizumab plus bevacizumab had less interference of symptoms with their day-to-day life at most visits compared with patients treated with sunitinib.”

Learn more by clicking here.